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Abstract
This commentary to the editorial of Hajizadeh argues that the economic, social and health consequences of 
legalizing cannabis in Canada will depend in large part on the exact stipulations (mainly from the federal 
government) and on the implementation, regulation and practice of the legalization act (on provincial and 
municipal levels). A strict regulatory framework is necessary to minimize the health burden attributable to 
cannabis use. This includes prominently control of production and sale of the legal cannabis including control of 
price and content with ban of marketing and advertisement. Regulation of medical marijuana should be part of 
such a framework as well.
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The Current Situation in Canada: Waiting for a Federal 
Legalization Framework
Canada will become one of the first countries to fully legalize 
cannabis consumption on a national level (as announced at 
the United Nations General Assembly Special Session on 
drugs 2016),1 and Hajizadeh2 tries to summarize the potential 
economic, social and health consequences of such a move. We 
will argue here that all of these consequences will depend in 
large part on the exact stipulations (mainly from the federal 
government) and on the implementation, regulation and 
practice of the legalization act on provincial and municipal 
levels (for similar considerations for the United States see).3,4 
The federal government’s point person on the legalization 
of marijuana has declared that legalization would be 
implemented within a public health framework,5 and he spoke 
about strict controls (for a general overview on regulation and 
public health).6,7 However, even with such a framework there 
are different options, and further, the provinces will likely be 
given some latitude to regulate legal cannabis. The devil will 
be in the details. 
As a general background, substance policies matter.8 
Psychoactive substance use is among the leading risk 
factors for global burden of disease,9 and the last decades 
have shown that wrong policies may even lead to reversals 
in the monotonous upward trends of life expectancy that 
characterized most of the last century.10,11 The importance 
for public health of getting substance policies right has been 
shown in regards to legal substances,12,13 illegal substances,14 
and pharmaceuticals10 (for more general discussions see 8,10,15).
There are also economic costs to society, which depend on 
the policies implemented,16 and these costs affect not only the 
healthcare system but also the educational, legal, and other 
systems.17,18 The mere fact of whether a substance use is legal 
or not does not predict the resulting burden of disease, and 
consequently, legalization may result in negative or positive 
health outcomes, depending on how the legal and regulatory 
framework is designed and implemented.
Given the above background and the situation in Canada, the 
current contribution has two main objectives. First, we will 
give an overview of how regulations and implementation may 
impact on the main behavioural drivers of cannabis-related 
harm. Second, we give a few examples of how the details of 
these regulations may impact on the actual outcomes.
Cannabis-Related Health Harms and Policy
As cannabis use per se in a legalized framework has no 
criminal consequences, we need to establish regulations 
which would reduce the cannabis use behaviours linked to 
most of the health burden. This current health burden mainly 
comprises cannabis use disorders as the most important non-
fatal health outcome, and injury fatalities, especially traffic 
injury fatalities19 as the most important mortality outcome 
(for a quantification for Canada see20,21). The most important 
behaviours linked to burden are the following (see also21):
•	 Heavy use/frequent use over time22,23 
•	 Mixing of cannabis use and operating machinery (in 
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particular driving a car)24,25
•	 Using cannabis with high tetrahydrocannabinol (THC)26
•	 Smoking cannabis, especially mixed with tobacco22
•	 Using cannabis in early and mid-adolescence26,27 
How could regulation play a role in reducing these behaviours?
Education and guidelines may play a role in reducing heavy 
and frequent use (for guidelines see22). One way to finance 
such efforts would be via a dedicated tax, which would be 
used for prevention, research, education, and treatment. 
Examples of such taxes exist in the alcohol and tobacco field,28 
and justification could be derived from classical economic 
theory.29,30 Another way to impact on frequency of use, 
especially in adolescents (above legal age) and young adults, 
is via price (and indirectly via taxation). Alcohol and tobacco 
policies have shown that price is a powerful tool to influence 
level of use,31,32 and specific taxation schemes may even impact 
on onset of substance use.33,34 Finally, again drawing from 
alcohol and tobacco, a ban on marketing and advertisement 
contributes to establish cannabis as no ordinary commodity 
where certain caution in use patterns are required.15
Mixing cannabis use and driving (or operating machinery) 
should be avoided independently of the policy environment. 
Even though there had been studies showing no significant 
results of cannabis use on driving,35 systematic reviews of all 
relevant studies and subsequent pooling of results show an 
impact,24,25 and the biological pathways on reaction time and 
psychomotor coordination are similar between operating a 
car and other machinery.19,36 Thus, per se laws similar to the 
ones governing blood alcohol level to prevent such behaviour 
(ie, no driving or operating machinery with active levels of 
Δ9-tetrahydrocannabinol which could impair reaction time 
and psychomotor coordination) should be established.37,38
Using cannabis in early and mid-adolescence poses specific 
health risks,26,27 including risk on the developing brain. Thus, 
a minimum purchasing age needs to be implemented similar 
to alcohol39 (which has similar or even more detrimental 
effects40). Moreover, this laws needs to be well-enforced, and 
experience with alcohol has shown that best enforcement can 
be achieved can be achieved through a state monopoly on 
sales.39 
Using cannabis with high tetrahydrocannabinol content is 
becoming more common in some countries,41 and the 
effects on health (compared to lower THC) can be more 
detrimental.19,26 Obviously, THC content can and should be 
regulated in legalized environments, similar to regulated 
ingredients in food, alcoholic beverages or other legal 
substances. This could take the form of pricing policies that 
make higher-potency products are more expensive than those 
with lower potency.
Smoking cannabis, especially with tobacco, adds additional 
risk, especially with respect to respiratory disease.19 Again, 
there should be more education on these specific risks, and 
there should be encouragement of smoke-free and tobacco-
free modes of cannabis use in a legalized environment.
Furthermore, there may be some short-term public health 
consequences of legalization related to cannabis-related 
emergency department visits,42,43 which may be avoided with 
specific implementations (see recent proposed changes in 
Colorado as listed in43).
… and Further Details
The above examples show that regulation can contribute to 
a reduction in behaviours which have been associated with 
health harm. However, things are not that simple. Much will 
depend on controlling the way the legal substance is produced 
and sold (and we will restrict the following discussion to the 
latter point).
For cannabis another complication comes into play, which 
does not exist for other legal psychoactive substances 
like alcohol or tobacco: medical use.44 Medical marijuana 
programs have proliferated in the United States and Canada,45 
in part because they allowed higher availability of an illegal 
substance without changing narcotic laws. Depending on 
the jurisdiction, some of the usual regulatory principles of 
pharmaceutical product approval are not required, with 
the consequence that cannabis is frequently prescribed 
for conditions where its effect is not clear46 or may even be 
detrimental, such as depression or anxiety disorders.47-49 In a 
regulated legal environment, medical use of cannabis should 
be restricted to disorders where clear evidence of effectiveness 
has been established through the same rigorous process of 
approval as other pharmaceuticals, usually via a series of 
phases ending with randomized controlled trials in humans 
to establish efficacy in treating certain conditions.50 This 
would ensure avoidance of problems such as mis-indications 
as mentioned above. It should be stated that medical research 
with cannabis has historically faced barriers in the United 
States,51 but this is not an issue in Canada.
Even if these principles are adhered to, there is a question 
of what should happen to currently established cannabis 
dispensaries in the interim, or in the long run. The controversy 
in Toronto after the recent police raids of illegal dispensaries 
provides some illustration.52 In these controversies, some 
argued that no police action should be have been taken 
because cannabis will be legalized within less than a year, 
while others maintained that they were justified because the 
dispensaries violate the current law for medical marijuana. In 
addition, the type of dispensaries setting up shop in Toronto 
may not have a place in the new legal framework, but their 
presence (and increasing numbers) is creating facts on the 
ground. The longer this persists, the more challenging it 
will be for the federal government’s preferred legal cannabis 
framework to succeed.
Again, the situation is not entirely historically new as illegal 
producers and sellers of alcohol had to be integrated into a 
new system after the prohibition of alcohol was lifted in 
North America. This worked quite well, and moonshine and 
other illicitly produced alcohol currently play little role in 
either Canada or the United States.53 The creation of a state 
monopoly that offers market prices to producers may be a 
solution here, which had worked for unrecorded alcohol in 
Germany at the time.54 
Thus, while the debate on legalization of cannabis has often 
been categorical between its proponents and adversaries, the 
true challenge will be the exact implementation. If Canada 
does not get these regulations correct, public health problems 
may be created, with subsequent costs to society, which 
may exceed the new tax revenues.16 On the other hand, if 
regulations are carefully introduced based on best available 
evidence (and admittedly some of this evidence will come 
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from other fields),55 with independent monitoring and 
surveillance, and with openness to change in case of negative 
developments, Canada has a chance to become a leader as an 
experimenting society.56-58
Ethical issues 
Not applicable. 
Competing interests 
Authors declare that they have no competing interests.
Authors’ contributions 
JR wrote the drafts for the original and revised version of the 
commentary.  All authors significantly contributed to the text, and have 
approved of the final version.
Authors’ affiliations 
1Institute for Mental Health Policy Research, Centre for Addiction and 
Mental Health (CAMH), Toronto, ON, Canada. 2Addiction Policy, Dalla 
Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 
3Institute of Medical Science, University of Toronto, Faculty of Medicine, 
Toronto, ON, Canada. 4Department of Psychiatry, University of Toronto, 
Toronto, ON, Canada. 5Institute of Clinical Psychology and Psychotherapy, 
Technische Universität Dresden, Dresden, Germany. 6Center of 
Clinical Epidemiology and Longitudinal Studies (CELOS), Technische 
Universität Dresden, Dresden, Germany. 7Campbell Family Mental Health 
Research Institute, CAMH, Toronto, ON, Canada. 8Communications and 
Partnerships, CAMH, Toronto, ON, Canada. 9Centre for Applied Research 
in Mental Health and Addiction, Faculty of Health Sciences, Simon Fraser 
University, Vancouver, BC, Canada.
References
1. Government of Canada. Plenary statement for the Honourable 
Jane Philpott Minister of Health – UNGASS on the world drug 
problem. http://news.gc.ca/web/article-en.do?nid=1054489 
Accessed 06/06/2016. Published 2016.
2. Hajizadeh M. Legalizing and regulating marijuana in Canada: 
review of potential economic, social, and health impacts. Int J 
Health Policy Manag. 2016;5:1-4. doi:10.15171/ijhpm.2016.63
3. Caulkins JP, Kilmer B, Kleinman MA, et al. Options and isses 
regarding marijuana legalization: Rand Corporation; 2015: 
http://www.rand.org/pubs/perspectives/PE149.html. Accessed 
Accessed August 12, 2016.
4. Caulkins JP, Kilmer B, Kleinman MA, et al. Considering marijuana 
legalization: Insights for Vermont and other jurisdictions. Santa 
Monica, CA: Rand Corporation; 2015. 
5. LeBlanc D. Legalizing marijuana will come with strict controls, 
MP Bill Blair says. The Globe and Mail. January 12, 2016. 
http://www.theglobeandmail.com/news/politics/legalizing-
marijuana-will-come-with-strict-controls-mp-bill-blair-says/
article28137320/. 
6. Crépault JF, Rehm J, Fischer B. Cannabis policy framework by 
the centre for addiction and mental health: a proposal for a public 
health approach to cannabis policy in Canada. Int J Drug Policy. 
2016; forthcoming. doi:10.1016/j.drugpo.2016.04.013
7. Centre for Addiction and Mental Health. Cannabis Policy 
Framework. Toronto, Canada: Centre for Addiction and Mental 
Health; 2014.
8. Rehm J, Anderson P, Fischer B, Gual A, Room R. Policy 
implications of marked reversals of population life expectancy 
caused by substance use. BMC Med. 2016; 14:42. doi:10.1186/
s12916-016-0590-x
9. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, 
regional, and national comparative risk assessment of 79 
behavioural, environmental and occupational, and metabolic 
risks or clusters of risks in 188 countries, 1990–2013: a 
systematic analysis for the Global Burden of Disease Study 
2013. Lancet. 2015;386(10010):2287-2323. doi:10.1016/S0140-
6736(15)00128-2
10. Deaton A. The Great Escape – health, wealth and the origins of 
inequality. Princeton, NJ: Princeton University Press; 2013. 
11. Riley JC. Rising Life Expectancy: A Global History. Cambridge, 
UK: Cambridge University Press; 2001. 
12. Leon DA, Chenet L, Shkolnikov V, et al. Huge variation in 
Russian mortality rates 1984-1994: artefact, alcohol, or what? 
Lancet. 1997; 350(9075):383-388. 
13. Bhattacharya J, Gathmann C, Miller G. The Gorbachev Anti-
Alcohol Campaign and Russia’s Mortality Crisis. Am Econ J Appl 
Econ. 2013;5(2):232-260. 
14. Aburto JM, Beltrán-Sánchez H, García-Guerrero VM, Canudas-
Romo V. Homicides in Mexico reversed life expectancy gains 
for men and slowed them for women, 2000-10. Health Aff. 
2016;35(1):88-95. doi:10.1377/hlthaff.2015.0068
15. Anderson P, Braddick F, Conrod P, et al. The New Governance 
of Addictive Substances and Behaviours. Oxford, UK: Oxford 
University Press; 2016. 
16. Kilmer B, Caulkins JP, Pacula RL, MacCoun RJ, Reuter PH. 
Altered state? Assessing How Marijuana Legalization in 
California Could Influence Marijuana Consumption and Public 
Budgets. Santa Monica, CA: RAND Corporation; 2010.
17. MacQueen K. Why it’s time to legalize marijuana. http://www.
macleans.ca/news/canada/why-its-time-to-legalize-marijuana/. 
Accessed August 12, 2016. Published 2013.
18. Shanahan M, Ritter A. Cost benefit analysis of two policy 
options for cannabis: status quo and legalisation. PLoS One. 
2014;9(4):e95569. doi:10.1371/journal.pone.0095569
19. World Health Organization (WHO). The health and social effects 
of nonmedical cannabis use. Geneva, Switzerland: WHO; 2016. 
20. Fischer B, Imtiaz S, Rudzinski K, Rehm J. Crude estimates 
of cannabis-attributable mortality and morbidity in Canada–
implications for public health focused intervention priorities. J 
Public Health. 2016;38(1):183-188. doi:10.1093/pubmed/fdv005
21. Imtiaz S, Shield KD, Roerecke M, et al. The burden of disease 
attributable to cannabis use in Canada in 2012. Addiction. 
2016;111:653-662. 
22. Fischer B, Jeffries V, Hall W, Room R, Goldner E, Rehm J. Lower 
risk cannabis use guidelines for Canada (LRCUG): a narrative 
review of evidence and recommendations. Can J Public Health. 
2011;102(5):324-327. 
23. Rehm J, Marmet S, Anderson P, et al. Defining substance use 
disorders: do we really need more than heavy use? Alcohol 
Alcohol. 2013;48(6):633-640. doi:10.1093/alcalc/agt127
24. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis 
consumption and motor vehicle collision risk: systematic 
review of observational studies and meta-analysis. Br Med J 
2012344:e536. doi:10.1136/bmj.e536
25. Rogeberg O, Elvik R. The effects of cannabis intoxication 
on motor vehicle collision revisited and revised. Addiction. 
2016;111(8):1348-1359. doi:10.1111/add.13347
26. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health 
effects of marijuana use. N Engl J Med. 2014;370(23):2219-
2227. doi:10.1056/NEJMra1402309
27. George T, Vaccarino F. Substance abuse in Canada: the effects 
of cannabis use during adolescence. Ottawa, ON: Canadian 
Centre on Substance Abuse; 2015. 
28. Chaloupka FJ, Yurekli A, Fong GT. Tobacco taxes as a tobacco 
control strategy. Tob Control. 2012;21:172-180. doi:10.1136/
tobaccocontrol-2011-050417
29. Thomas B. Issues in the design of excise tax. J Econ Perspect. 
1994;8(1):133-151.
30. Pigou AC. The Economics of Welfare. London: Macmillan; 1920. 
31. Chisholm D, Doran C, Shibuya K, Rehm J. Comparative cost-
effectiveness of policy instruments for reducing the global 
Rehm et al
International Journal of Health Policy and Management, 2017, 6(3), 173–176176
burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev. 
2006; 25(6):553-565. 
32. U.S. Department of Health and Human Services. The Health 
Consequences of Smoking—50 Years of Progress: A Report of 
the Surgeon General. Atlanta, GA: Department of Health and 
Human Services. Centers for Disease Control and Prevention. 
National Center for Chronic Disease Prevention and Health 
Promotion. Office on Smoking and Health; 2014.
33. Freedman KS, Nelson NM, Feldman LL. Smoking initiation 
among young adults in the United States and Canada, 1998-
2010: a systematic review. Prev Chronic Dis. 2012;9:E05. 
34. Sornpaisarn B, Shield KD, Cohen JE, Schwartz R, Rehm J. Can 
pricing deter adolescents and young adults from starting to drink: 
an analysis of the effect of alcohol taxation on drinking initiation 
among Thai adolescents and young adults. J Epidemiol Glob 
Health. 2015;5(Suppl 4):S45-S57. 
35. National Highway Traffic Safety Administration. NHTSA releases 
two new studies on impaired driving on U.S. roads. 2015. http://
www.nhtsa.gov/About+NHTSA/Press+Releases/2015/nhtsa-
releases-2-impaired-driving-studies-02-2015. Accessed June 1, 
2016.
36. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis 
use on human behavior, including cognition, motivation, and 
psychosis: a review JAMA Psychiatry. 2016; 73(3):292-297. 
doi:10.1093/schbul/sbv010
37. World Health Organization (WHO). Global status report on road 
safety 2015. Geneva, Switzerland: WHO; 2015.
38. Wong K, Brady JE, Li G. Establishing legal limits for driving 
under the influence of marijuana. Inj Epidemiol. 2014;1:26. 
doi:10.1186/s40621-014-0026-z
39. Babor T, Caetano R, Casswell S, et al. Alcohol: No ordinary 
commodity. Research and public policy. 2nd ed. Oxford: Oxford 
University Press; 2010. 
40. Squeglia LM, Jacobus J, Tapert SF. The influence of substance 
use on adolescent brain development. Clin EEG Neurosci. 
2009;40(1):31-38. 
41. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of 
Delta9-THC and other cannabinoids in confiscated cannabis 
preparations from 1993 to 2008. J Forensic Sci. 2010;55(5):1209-
1217. doi:10.1111/j.1556-4029.2010.01441.x
42. Davis JM, Mendelson B, Berkes JJ, Suleta K, Corsi KF, Booth 
RE. Public health effects of medical marijuana legalization in 
Colorado. Am J Prev Med. 2016;50(3):373-379. doi:10.1016/j.
amepre.2015.06.034
43. Wang GS, Le Lait MC, Deakyne SJ, Bronstein AC, Bajal L, 
Roosevelt G. Unintentional pediatric exposures to marijuana 
in Colorado, 2009-2015. JAMA Pediatr. 2016;e160971. 
doi:10.1001/jamapediatrics.2016.0971.
44. Leung L. Cannabis and its derivatives: review of medical 
use. The Journal of the American Board of Family Medicine. 
2011;24(4):452-462. 
45. ProCon. 25 Legal marjuana states and DC - Laws, fees, and 
possession limits. 2016. http://medicalmarijuana.procon.org/
view.resource.php?resourceID=000881#summary. Accessed 
June 27, 2016.
46. Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic 
purposes: Patient characteristics, access, and reasons for use. 
Int J Drug Policy. 2013;24:511-516. 
47. Feingold D, Weiser M, Rehm J, Lev-Ran S. The association 
between cannabis use and mood disorders: A longitudinal 
study. Journal of Affective Disorder. 2015; 1(172):211-218. 
doi:10.1016/j.jad.2014.10.006
48. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, 
Rehm J. The association between cannabis use and depression: 
a systematic review and meta-analysis of longitudinal 
studies. Psychol Med. 2014;44(4):797-810. doi:10.1017/
s0033291713001438
49. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use 
and risk of psychotic or affective mental health outcomes: 
a systematic review. Lancet. 2007;370(9584):319-328. 
doi:10.1016/s0140-6736(07)61162-3
50. Health Canada. How drugs are reviewed in Canada. http://
www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/fs-fi/reviewfs_
examenfd-eng.php. Accessed  June 1, 2016. Published 2015.
51. Stith SS, Vigil JM. Federal barriers to Cannabis research. 
Science. 2016; 352(6290):1182. doi:10.1126/science.aaf7450
52. CBC News. Second round of pot shop raids as police descend 
on city dispensaries. 2016. http://www.cbc.ca/news/canada/
toronto/second-round-of-pot-shop-raids-as-police-descend-on-
city-dispensaries-1.3649510. Accessed June 27, 2016.
53. Rehm J, Kailasapillai S, Larsen E, et al. A systematic review 
of the epidemiology of unrecorded alcohol consumption and 
the chemical composition of unrecorded alcohol. Addiction. 
2014;109(5):880-893. doi:10.1111/add.12498
54. Lachenmeier DW, Rehm J. Von Schwarzbrennern und Vieldrinkern. 
Die Auswirkungen des deutschen Branntweinmonopols auf den 
gesundheitlichen Verbraucherschutz. [Bootleggers and heavy 
drinkers. The impact of the German alcohol monopoly on public 
health and consumer safety]. Sucht. 2010;56(2):91-93. 
55. Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP. 
Developing public health regulations for marijuana: Lessons from 
alcohol and tobacco. Am J Public Health. 2014;104(6):1021-
1028. 
56. Campbell DT. Reforms as experiments. American Psychologist. 
1969;24:409-429. 
57. Campbell DT. The social scientist as methodological servant of 
the experimenting society. Policy Stud J. 1973;2:72-75. 
58. Fischer B, Rehm J, Crépault JF. Realistically furthering the goals 
of public health by cannabis legalization with strict regulation: 
Response to Kalant. Int J Alcohol Drug Res. 2016. pii: S0955-
3959(16)30196-7. doi:10.1016/j.drugpo.2016.06.014
